Company:  APELLIS PHARMACEUTICALS, ... (APLS)
Form Type:  3
Filing Date:  4/15/2019 
CIK:  0001492422 
Address:  6400 WESTWIND WAY
SUITE A
 
City, State, Zip:  CRESTWOOD, Kentucky 40014 
Telephone:  502-241-4114 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$23.40  
Change: 
-0.42 (-1.76%)  
Trade Time: 
Jun 26  
Market Cap: 
$1.48B
Trade APLS now with 

© 2019  
Description of Business
We are a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. We believe that this approach can result in broad inhibition of the principal pathways of the complement system and has the potential to effectively control a broad array of complement-dependent autoimmune and inflammatory diseases. We have the most advanced clinical program targeting C3 with Phase 3 clinical trials of our lead product candidate, APL-2, in multiple indications. We believe that APL-2 has the potential to be a best-in-class treatment that may address the limitations of existing treatment options or provide a treatment option where there currently is none.
Register and access this filing in:     
  FORM 3
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES
  EXHIBIT 24
    LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS